Advertisement
"Expanding our CytoCare relationship with Health Robotics to theseadditional products has been an strategic goal of ours for quite some time,as we believe that the cost and small footprint of these innovative productstogether with their applicability to all Korean acute care hospitals asopposed to only Cancer Centers gives us the ability to enhance our objectiveto maximize market share and to offer end-to-end IV Automation solutions toour customers in the Republic of Korea", stated Bum Kyo Lee, CEO ofBioRobotics.
Advertisement
i.v.STATION represents a revolutionary approach in the quest for safe,accurate, efficient, cost effective, and ready-to-administer intravenouspatient doses. It offers unprecedented reduction of medication errors,ISO-compliant accuracy, improved sterility, and clinician labor savings: allwithin a scalable, cost-effective, distributed, and fail-safe architecture.i.v.SOFT constitutes an ideal complement to CytoCare and i.v.STATION both asa means to back-up robotic devices and to direct excess IV Admixtureproduction demand and non-standard IV consumables (i.e. cassette pumps,ampoules, glass bottles, IV doses requiring the use of CSTDs, etc.) towardsLaminar Airflow Hoods.
"It is a pleasure to renew our commitment and strategic partnership withBioRobotics and to ship the first i.v.STATION robot to Korea for installationin December 2010. We are confident that BioRobotics' technical expertise withSurgery Robots positions them to take full advantage of our new products.Additionally, this new strategic agreement marks the significant milestonefor Health Robotics of completing mainland Asia marketing and servicechannels' coverage for i.v.STATION, with only Taiwan and Oceania channelstrategies remaining to be determined over the next few months", statedGaspar DeViedma, Health Robotics' Executive Vice President.
About BioRobotics:
Founded in 1995, BioRobotics is currently the leading medical roboticssupplier and the second largest medical importing business in the Republic ofKorea with US $27M import volume during the year 2008. The company originallystarted in the Aesthetic laser surgery and Cryosurgery medical sectors andfurther expanded into robotic surgery in 2005. In only 4 years since thelaunch of Oncology Robotics in its core market, BioRobotics has alreadyachieved twenty-four (24) installations of the daVinci(R) Surgical robot inthe Republic of Korea. For more information, please visit:http://www.biorobotics.co.kr/
About Health Robotics:
Health Robotics is the undisputed global leading supplier oflife-critical intra-venous medication robots, providing over 100 hospitalinstallations in 5 continents with robotics technology and softwareautomation solutions deployed utilizing virtual high-availability technology.Its world-leading solutions CytoCare(TM) [hazardous IVs], i.v.STATION(TM)[non-hazardous IVs], i.v.SOFT(TM) [manual compounding software],MEDarchiver(TM) [life-critical clinical information system], andTPNstation(TM) [totally-automated parenteral nutrition] have and will greatlycontribute to ease hospitals' growing pressures to improve patient safety,increase throughput and contain costs. Through the effective and efficientproduction of sterile, accurate, tamper-evident and ready-to-administer IVs,Health Robotics' solutions help hospitals eliminate life-threatening drug anddiluent exchange errors, decrease other medical mistakes and sterility risks,work more efficiently, reduce waste and controlled substances' diversion, anddiminish the gap between rising patient volume/acuity and scarce medical,nursing, and pharmacy staff. For more information, please visit:http://www.health-robotics.comFor additional information, please contact: Claudia Flaim, Health Robotics' Marketing Coordinator Altmanstrasse 9/A, Bozen, I-39100 [email protected] Phone: +39-0471-200-372 Bum Kyo Lee, BioRobotics' CEO 5F 5-36 Hyochang-dong, Yongsan-ku, Seoul, Korea [email protected] Phone: +82-270-15266
SOURCE Health Robotics
